Sangamo Therapeutics (SGMO)

• Market cap: $155M
• 1 day: -0.29%
• 5 days: -0.95%
• 1 month: -12.97%
• 3 months: 6.13%
• 6 months: -49.24%
• Year to date: -54.63%
• 1 year: -38.5%
• 5 years: -95.24%
• 10 years: -93.32%
• Sector: Healthcare
• Industry: Biotechnology

About: Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.

Employees: 183

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

4% more call options, than puts

Call options by funds: $756K | Put options by funds: $727K

6% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 32

1.42% less ownership

Funds ownership: 23.39% [Q1] → 21.97% (-1.42%) [Q2]

7% less funds holding

Funds holding: 121 [Q1] → 112 (-9) [Q2]

20% less capital invested

Capital invested by funds: $34.5M [Q1] → $27.7M (-$6.75M) [Q2]

33% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 24

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $10
• Avg. target: $10
• High target: $10

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Patrick R. Trucchio	$10	Buy Reiterated	4 Sep 2025
HC Wainwright & Co. Patrick Trucchio	$10	Buy Reiterated	24 Jun 2025